3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Pain, Postoperative
19
Breast Neoplasms
12
Brain Neoplasms
11
Agnosia
7
Neoplasms
6
Delirium
5
Thyroid Neoplasms
4
Stomach Neoplasms
4
Lung Neoplasms
4
Pituitary Neoplasms
3
Pain
3
Inflammation
3
Emergence Delirium
3
Colorectal Neoplasms
3
Chronic Pain
3
Urinary Bladder Neoplasms
2
Supratentorial Neoplasms
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Pheochromocytoma
2
Pain, Intractable
2
Neoplasm Metastasis
2
Liver Neoplasms
2
Dexmedetomidine
2
Colonic Neoplasms
2
Central Nervous System Diseases
2
Thrombosis
1
Spinal Cord Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Sleep Deprivation
1
Interventions
Tamoxifen
4
Exercise
3
pyrotinib
2
abemaciclib
2
Paclitaxel
2
Metformin
2
Letrozole
2
Cyclophosphamide
2
Control Groups
2
Capecitabine
2
Bupivacaine
2
Aromatase Inhibitors
2
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
palbociclib
1
iniparib
1
exemestane
1
durvalumab
1
darolutamide
1
Yoga
1
Waiting Lists
1
Vitamin D
1
Tretinoin
1
Trastuzumab
1
Tocopherols
1
Thioctic Acid
1
Standard of Care
1
Sodium Chloride
1
Self-Help Groups
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Breast Cancer Female
×
Dexmedetomidine
×
Clear all
NCT03063073
2026-02-12
pec's
South Egypt Cancer Institute
Phase 3
Completed
60 enrolled